Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARDBiotechnology
+$0.09 today
- Market cap
- $86.45M
- Beta
- 4.47
- P/E (TTM)
- -1.2
- EPS (TTM)
- -$3.20
Volume 1.32M
Average 0.18M
AARD Total Assets
Everything the company owns or controls; equal to total liabilities plus equity.
Aardvark Therapeutics, Inc. Common StockNASDAQ: AARD
Total Assets · Q1 FY2026 · quarter ended Mar 2026
Total assets falls 37.2% from a year ago
Total assets stood at $98.59M at the end of Q1 FY2026, down 37.2% from a year earlier and down 15.9% from the prior quarter. Over 3 fiscal years it compounded at +91.2% a year.
Context
- Total assets increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total assets keeps falling in the next quarterly balance sheet after a -37.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Assets history
USD · from the balance sheet
- Latest · FY2025
- 117.18M USD
- Year-over-year change
- +51.2%
- 3-year CAGR
- +91.2%
| Period | Period end | Total Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 117.18M | +51.2% |
| FY2024 | 2024-12-31 | 77.51M | +635.6% |
| FY2023 | 2023-12-31 | 10.54M | -37.1% |
| FY2022 | 2022-12-31 | 16.76M | — |
Total Assets vs competitors
How AARD compares with its peers on the latest reported figures
- AARD's Mar 2026 total assets of $98.59M is the 10th highest of the 11 companies compared; the peer median is $163.39M.
- Its year-over-year change of -37.2% is the 9th highest of 11, against a peer median of -10.1%.
- Over three fiscal years its annual growth of +91.2% compares with a peer median of -14.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR |
|---|---|---|---|---|
| Mar 2026 | $314.7M | -2.6% | -9.6% | |
| Mar 2026 | $235.51M | +137.8% | +36.3% | |
ZURAZura Bio Limited | Mar 2026 | $228.64M | +32.5% | +178.7% |
| Mar 2026 | $222.17M | -14.1% | -21.2% | |
| Mar 2026 | $177.78M | -21.9% | -18.3% | |
| Mar 2026 | $149M | -45.6% | -22.3% | |
EPRXEupraxia Pharmaceuticals Inc. | Mar 2026 | $145.83M | +398.9% | +49.3% |
| Mar 2026 | $135.07M | -6.2% | -19.2% | |
| Mar 2026 | $99.89M | -27.9% | +51.7% | |
| Mar 2026 | $98.59M | -37.2% | +91.2% | |
| Mar 2026 | $64.3M | -52.7% | -24.3% | |
| Peer median (excluding AARD) | $163.39M | -10.1% | -14.0% | |
Competitors are the stored peer set for AARD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARD
Intrinsic Alpha fair value
Locked
Current Price
$3.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.